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Background: EC is common and incidence has increased by 65% in 40 years. There are no 
validated biomarkers or approved targeted therapies in clinical use. This study evaluates a 
novel biomarker panel in EC by correlating clinico-pathological features and tumour tissue 
expression levels of p53, PTEN, phospho-P70S6K (pS6), phospho-Stathmin (pSTMN). pS6 
and pSTMN activity is influenced by PI3K/Akt pathway activation which frequently occurs in 
EC. 
Methods: The 144 EC patients who had primary surgery from January 2006 to December 
2010 at University College London Hospital were retrospectively identified and included in 
this analysis. Patient characteristics are shown in Table 1. Antibodies for p53, PTEN, pS6 
and pSTMN were optimised for use in this study. IHC was performed on surgical resection 
specimens. Standard scoring methods incorporating percentage of cells stained and staining 
intensity were applied.  
Results: Univariate analysis for disease specific survival (DSS) showed, as expected, non-
endometrioid histology, grade (G)3 tumour, presence of lymphovascular invasion or 
myometrial invasion (MI) and advanced FIGO stage conferred poor DSS. The 
overexpression of p53 and pSTMN was also associated with poor DSS. In multivariate 
analysis G3 histology, MI, p53 and pSTMN overexpression were the only factors that 
remained significantly associated with poor DSS. 
Conclusions: We demonstrate for the first time that p53 and pSTMN overexpression are 
independent predictors of DSS in EC and may be useful prognostic biomarkers. 
Overexpression of pSTMN may predict sensitivity to PI3K pathway inhibitors in EC. 
Prospective evaluation is warranted in clinical studies. 
       
Variables Categories 
Univariable Analysis Multivariable Analysis 
n Deaths 
Hazard Ratio 
(95% CI) 
p 
value 
Hazard Ratio (95% 
CI) p value 
Age 
<65 59 7 
1.91 (0.79-4.62) 0.15 3.43 (0.33-35.14) 0.3 
≥65 85 17 
Histological  Endometrioid 128 16 
4.90 (2.09-11.48) <0.001 0.18 (0.008-3.99) 0.28 
sub-type 
Non-
endometrioid 16 8 
Grade 
1 and 2 94 5 
9.02 (3.36-24.19) <0.001 
47.14 (2.02-
1097.86) 
0.02 
3 50 19 
Size 
<3 cm 55 8 
1.18 (0.51-2.77) 0.69 NA NA 
≥3 cm 88 16 
Lymphovascular Absent 98 10 
4.16 (1.83-9.42) 0.001 2.51 (0.44-14.31) 0.3 
 Invasion Present 46 14 
Myometrial  <50% 74 8 
2.85 (1.21-6.71) 0.02 
129.09 (4.99-
3341.45) 
0.003 
Invasion ≥50% 67 16 
FIGO 1 and 2 118 12 
5.73 (2.41-13.65) <0.001 1.03 (0.09-11.57) 1.00 
  3 and 4 22 9 
Adjuvant  Didn’t receive 82 8 
2.23 (0.92-5.38) 0.07 0.31 (0.03-2.9) 0.3 
Radiotherapy Received 57 13 
Adjuvant  Didn’t receive 112 13 
2.79 (1.19-6.53) 0.02 0.33 (0.03-3.61) 0.36 
Chemotherapy Received 28 9 
p53  Negative 74 7 
2.9 (1.18-7.11) 0.02 
64.68 (1.59-
2637.75) 
0.03 
Expression Positive 55 15 
PTEN  Negative 99 13 
2.22 (0.92-5.37) 0.08 4.44 (0.85-23.12) 0.07 
Expression Positive 28 8 
phospho-
P70S6K  
Negative 
 32 5 1.27 (0.47-3.41) 0.64 NA NA 
Expression Positive 96 18 
phospho-
stathmin  
Negative 
98 5 12.34 (4.48-
34.00) 
<0.001 17.23 (1.03-286.91) 0.047 
Expression Positive 32 15 
Table-1. Cox proportional hazard regression model comparing clinico-pathological features and biomarker expression with DSS. NA – not applicable. HR- 
hazard ratio. 
